NEW YORK (GenomeWeb) – Signal Genetics today announced that the College of American Pathologists has awarded accreditations to the firm's Little Rock, Ark.-based laboratory.
"This further demonstrates our company's dedication to providing a quality diagnostic to patients suffering from multiple myeloma, and the physicians who treat them, in order to improve individual care," Signal CEO Sam Riccitelli said in a statement.
Carlsbad, Calif.-based Signal Genetics provides oncology molecular diagnostic services, offering the MyPRS microarray gene expression profiling assay for multiple myeloma. In February, the firm closed a $9 million public offering.